“Efficacy and Safety of up to Two Years of Tralokinumab Treatment in Adults of Different Racial Subgroups With Moderate-to-Severe Atopic Dermatitis”. 2022. SKIN The Journal of Cutaneous Medicine 6 (6): s74. https://doi.org/10.25251/skin.6.supp.74.